Immunosenescence and hurdles in the clinical management of older HIV-patients

M Ripa, S Chiappetta, G Tambussi

Research output: Contribution to journalArticlepeer-review


People living with HIV (PLWH) who are treated with effective highly active antiretroviral therapy (HAART) have a similar life expectancy to the general population. Moreover, an increasing proportion of new HIV diagnoses are made in people older than 50 y. The number of older HIV-infected patients is thus constantly growing and it is expected that by 2030 around 70% of PLWH will be more than 50 y old. On the other hand, HIV infection itself is responsible for accelerated immunosenescence, a progressive decline of immune system function in both the adaptive and the innate arm, which impairs the ability of an individual to respond to infections and to give rise to long-term immunity; furthermore, older patients tend to have a worse immunological response to HAART. In this review we focus on the pathogenesis of HIV-induced immunosenescence and on the clinical management of older HIV-infected patients. © 2017 Taylor & Francis
Original languageEnglish
Pages (from-to)508-528
Number of pages21
Issue number5
Publication statusPublished - 2017


Dive into the research topics of 'Immunosenescence and hurdles in the clinical management of older HIV-patients'. Together they form a unique fingerprint.

Cite this